Stable neurological function in subjects treated with 2'3'dideoxyinosine

J. J. Sidtis; U. Dafni; Peter Slasor; C. Hall; R. W. Price; K. Kieburtz; T. Tucker; D. B. Clifford

doi:10.3109/13550289709018299

Stable neurological function in subjects treated with 2'3'dideoxyinosine

J. J. Sidtis, U. Dafni, Peter Slasor, C. Hall, R. W. Price, K. Kieburtz, T. Tucker, D. B. Clifford

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

AIDS Dementia Complex (ADC) is a frequent and devastating complication of HIV infection. There is evidence that zidovudine (ZDV) has an effect in alleviating the symptoms of ADC, and may have a role in its prevention. It is therefore important that new antiretroviral therapies be evaluated not only for the risk of neurologic side effects, but also for their relative efficacy to ZDV in the prevention of ADC. The present study reports the effects of 2'3'dideoxyinosine (DDI, didanosine, Videx) therapy on neuropsychological performance in the context of several large clinical trials targeting advanced systemic HIV-1 infection. Subjects treated with DDI had stable neurologic performance in quantitative tests over a 1 year period and were similar to zidovudine treated subjects.

Original language	English
Pages (from-to)	233-240
Number of pages	8
Journal	Journal of NeuroVirology
Volume	3
Issue number	3
DOIs	https://doi.org/10.3109/13550289709018299
State	Published - Jun 1997

Keywords

AIDS dementia
Acquired immunodeficiency syndrome
DDI
Didanosine
HIV
Zidovudine

Access to Document

10.3109/13550289709018299

Cite this

@article{b15f5ae9914548ad9baff85e44ffc678,

title = "Stable neurological function in subjects treated with 2'3'dideoxyinosine",

abstract = "AIDS Dementia Complex (ADC) is a frequent and devastating complication of HIV infection. There is evidence that zidovudine (ZDV) has an effect in alleviating the symptoms of ADC, and may have a role in its prevention. It is therefore important that new antiretroviral therapies be evaluated not only for the risk of neurologic side effects, but also for their relative efficacy to ZDV in the prevention of ADC. The present study reports the effects of 2'3'dideoxyinosine (DDI, didanosine, Videx) therapy on neuropsychological performance in the context of several large clinical trials targeting advanced systemic HIV-1 infection. Subjects treated with DDI had stable neurologic performance in quantitative tests over a 1 year period and were similar to zidovudine treated subjects.",

keywords = "AIDS dementia, Acquired immunodeficiency syndrome, DDI, Didanosine, HIV, Zidovudine",

author = "Sidtis, {J. J.} and U. Dafni and Peter Slasor and C. Hall and Price, {R. W.} and K. Kieburtz and T. Tucker and Clifford, {D. B.}",

year = "1997",

month = jun,

doi = "10.3109/13550289709018299",

language = "English",

volume = "3",

pages = "233--240",

journal = "Journal of NeuroVirology",

issn = "1355-0284",

number = "3",

}

TY - JOUR

T1 - Stable neurological function in subjects treated with 2'3'dideoxyinosine

AU - Sidtis, J. J.

AU - Dafni, U.

AU - Slasor, Peter

AU - Hall, C.

AU - Price, R. W.

AU - Kieburtz, K.

AU - Tucker, T.

AU - Clifford, D. B.

PY - 1997/6

Y1 - 1997/6

N2 - AIDS Dementia Complex (ADC) is a frequent and devastating complication of HIV infection. There is evidence that zidovudine (ZDV) has an effect in alleviating the symptoms of ADC, and may have a role in its prevention. It is therefore important that new antiretroviral therapies be evaluated not only for the risk of neurologic side effects, but also for their relative efficacy to ZDV in the prevention of ADC. The present study reports the effects of 2'3'dideoxyinosine (DDI, didanosine, Videx) therapy on neuropsychological performance in the context of several large clinical trials targeting advanced systemic HIV-1 infection. Subjects treated with DDI had stable neurologic performance in quantitative tests over a 1 year period and were similar to zidovudine treated subjects.

AB - AIDS Dementia Complex (ADC) is a frequent and devastating complication of HIV infection. There is evidence that zidovudine (ZDV) has an effect in alleviating the symptoms of ADC, and may have a role in its prevention. It is therefore important that new antiretroviral therapies be evaluated not only for the risk of neurologic side effects, but also for their relative efficacy to ZDV in the prevention of ADC. The present study reports the effects of 2'3'dideoxyinosine (DDI, didanosine, Videx) therapy on neuropsychological performance in the context of several large clinical trials targeting advanced systemic HIV-1 infection. Subjects treated with DDI had stable neurologic performance in quantitative tests over a 1 year period and were similar to zidovudine treated subjects.

KW - AIDS dementia

KW - Acquired immunodeficiency syndrome

KW - DDI

KW - Didanosine

KW - HIV

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0030833604&partnerID=8YFLogxK

U2 - 10.3109/13550289709018299

DO - 10.3109/13550289709018299

M3 - Article

C2 - 9200072

AN - SCOPUS:0030833604

SN - 1355-0284

VL - 3

SP - 233

EP - 240

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

IS - 3

ER -

Stable neurological function in subjects treated with 2'3'dideoxyinosine

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this